Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?

VITOR ENNES-VIDAL1*, RUBEM FIGUEIREDO SADOCK MENNA-BARRETO2, MARTA HELENA BRANQUINHA3, ANDRÉ LUIS SOUZA DOS SANTOS3 and CLAUDIA MASINI D’AVILA-LEVY1

1 Laboratório de Estudos Integrados em Protozoologia, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil
2 Laboratório de Biologia Celular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil
3 Laboratório de Investigação de Peptídeos, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

(Received 14 June 2016; revised 1 September 2016; accepted 26 September 2016; first published online 21 November 2016)

SUMMARY

Leishmaniasis is a neglected disease, which needs improvements in drug development, mainly due to the toxicity, parasite resistance and low compliance of patients to treatment. Therefore, the development of new chemotherapeutic compounds is an urgent need. This opinion article will briefly highlight the feasible use of calpain inhibitors as leading compounds to search for new therapeutic options to treat leishmaniasis. The milestone of this approach is to take advantage on the myriad of inhibitors developed against calpains, some of which are in advanced clinical trials. The deregulated activity of these enzymes is associated with several pathologies, such as strokes, diabetes and Parkinson’s disease, to name a few. In Leishmania, calpain upregulation has been associated to drug resistance and virulence. Whereas the difficulties in developing new drugs for neglected diseases are more economical than biotechnological, repurposing approach with compounds already approved for clinical use by the regulatory agencies can be an interesting shortcut to a successful chemotherapeutic treatment for leishmaniasis.

Key words: Calpain inhibitors, leishmaniasis, repurpose approach, MDL28170.

INTRODUCTION

The Trypanosomatidae family, Kinetoplastea class, is composed of a large group of exclusively parasitic protozoa, some of which cause important diseases in humans (d’Avila-Levy et al. 2015). Altogether, about 37 million people worldwide are infected with Trypanosoma brucei, the aetiologic agent of African sleeping sickness; Trypanosoma cruzi, the causative agent of Chagas’ disease or American trypanosomiasis; and different species of the genus Leishmania, which are responsible for a wide spectrum of clinical manifestations known as cutaneous, mucocutaneous and visceral leishmaniasis (WHO, 2015). Since these diseases have been wiped out in the more developed parts of the world and persist only in the poorest, most marginalized communities and conflict areas, they are classified as neglected tropical diseases by the World Health Organization (WHO, 2015). Factors like malnutrition, weak immunity, illiteracy, lack of resources and environmental changes, as well as the migration of non-immune people to endemic areas, play important roles in the dynamic of these diseases (Desjeux, 2001; Alvar et al. 2006; Boelaert et al. 2010).

All the clinical manifestations collectively known as leishmaniasis comprise one of the most prevalent neglected diseases worldwide with more than 2 million new cases occurring annually and endangering around 350 million people in 98 countries in the tropics, sub-tropics and European Mediterranean area (WHO, 2015). Visceral leishmaniasis, also known as kala-azar, is the most severe one, and can be fatal if untreated. This clinical manifestation affects the vital organs of the body and is characterized by irregular bouts of fever, weight loss, anaemia, and swelling of the spleen and liver. If not fully healed, visceral leishmaniasis can progress to post-kalaazar dermal leishmaniasis, which is characterized by a hypopigmented macular, maculopapular and nodular rash. Cutaneous leishmaniasis, the most common form of the disease, causes ulcers on exposed skin areas of the body, leading to disfigurement, permanent scars, social stigma and in some cases disability. However, this is usually a self-healing illness. Finally, mucocutaneous leishmaniasis consists of the most destructi ve form of the disease, since it causes partial or total mutilation of mucous membranes in the nose, mouth and throat. In almost all cases, it may cause serious deformities (WHO, 2010; Alvar et al. 2012).

TREATMENT AND DRUG THERAPY

Despite the great advances in combating infectious diseases over the past century, the current therapy...
to treat neglected diseases, like leishmaniasis, is extremely limited to a handful of drugs that suffer from unacceptable toxicity, high costs, difficulties of administration and increasing treatment failures, since resistance to these compounds has become a severe problem (Cavalli and Bolognesi, 2009; Wilkinson and Kelly, 2009; Boelaert et al. 2010).

In view of this scenario, the development of new drugs is an urgent need, which has led to the investigation of several compounds chosen empirically, or through studies that identify promising metabolic targets to the rational drug design and selection (De Menezes et al. 2015).

The process of drug development is time consuming, laborious and expensive. On average, a drug is developed in 15–17 years, from the discovery process to pharmacological regulatory agencies approval. Before the availability for doctors to prescribe, millions are spent, starting from the discovery process that involves screening chemically diverse compounds (synthetic or natural sources), computational-assisted compound redesign, preclinical testing in cellular and animal models, to clinical trials and then the final approval (Fig. 1). Considering the neglected diseases, the reality is quite different, since the link with poverty results in low investment in rational drug development. A high number of patents are dead due to the failure of payment of maintenance cost, or revoked for not meeting patentability requirements, which seems to be an indication of the difficulties faced by research institutes and universities for disclosed compounds to reach the final stages of innovation and entering into the market (Machado-Silva et al. 2015). Consequently, governmental action is crucial to guarantee innovation and patient care and treatment. Therefore, considering that the challenges for the introduction of new compounds to treat neglected diseases are more economical than biological, repurpose drugs have potential benefits, such as, reducing the costs during discovery and development, preclinical laboratory tests and clinical phases (Andrews et al. 2014; Kwok and Koenigbauer, 2015) (Fig. 1).

**CALPAIN INHIBITORS**

Economically, drug-repurposing strategies have the potential to facilitate an effective drug development. As the cost associated with discovering and developing a new chemical entities may be around US$ 800 million and may take one to two decades, repurpose drugs have already proven to have considerable advantages (Ashburn and Thor, 2004; Taylor and Wainwright, 2005; Nwaka and Hudson, 2006; Andrews et al. 2014) (Fig. 1). Taking into consideration this last possibility, a family of neutral calcium-dependent cysteine peptidases, the calpains, calls attention because a huge effort has been made to develop means of identifying selective inhibitors (Carragher, 2006; Donkor, 2015). These enzymes are involved in a variety of calcium-regulated cellular processes, such as signal transduction, cytoskeleton remodelling, cellular proliferation and differentiation, sex determination, membrane fusion, environmental regulated processes and apoptosis. Besides their physiological roles, calpains unregulated activity in humans is implicated in several pathophysiological processes, such as, aging, muscular dystrophy, multiple sclerosis, cataract, arthritis, cancer, strokes, diabetes and neurological disorders (Alzheimer’s, Huntington’s and Parkinson’s diseases). It has been advocated that the specific inhibition of calpains under these condition can treat these pathologies. In addition to these pathologies, calpain unregulated activity also plays a crucial role in neuron death in traumatic spinal cord injury, and its specific inhibition can prevent apoptosis and restore transcription of proteolipid protein and myelin basic protein genes, which indicates the therapeutic efficacy of calpain inhibitors to rescue or prevent permanent disability. Therefore, prompt inhibition of calpains, if undertaken early enough after injury, could significantly spare many neurons (Huang and Wang, 2001; Battaglia et al. 2003; Saez et al. 2006; Zhang et al. 2015). To treat some of these pathologies, in the last 4 years, at least 52 calpain inhibitors were developed and screened (Donkor, 2015). Out of these, one is under phase I clinical trial to treat Alzheimer disease, and another compound presented promising
results in animal models to the treatment of cataracts and clinical trials will be performed by Calpain Therapeutics Co. (Table 1; Fig. 2). Up to date, calpain inhibitors display a wide range of potency, but low specificity, inhibiting also other cysteine and serine peptidases or even the proteasome (Low et al. 2016). Therefore, future efforts in the development of calpain inhibitors should not only concentrate on potency and selectivity of the inhibitors for calpain compared with other proteases but should also focus on achieving significant calpain isoform selectivity (Donkor, 2011).

Detailed studies on the kinetics and mechanism of action of calpain inhibitors allowed to classify them as: allosteric effectors, mechanism-based, tight binding, slow binding, affinity labels, suicide substrates, transition state analogues and dead-end inhibitors (Otto and Schirmeister, 1997; Vicik et al. 2006). Allosteric calpain inhibitors are known not to target the active site but most likely interact with allosteric sites, which are involved in catalysis and activation; as a result, these molecules may provide more therapeutic benefit than peptide inhibitors. An example is α-mercaptoacrylate PD150606, a potent and selective inhibitor of calpain-1 (Wang et al. 1996).

Active site-directed inhibitors, as the name suggests, interact directly with the active site. These compounds are usually peptidomimetics of calpain substrates, composed of modified amino acids that are recognized by the enzyme, and can be either reversible or irreversible inhibitors (Angelastro et al. 1990). Examples of the former include the synthetic compounds aldehydes, α-ketoheterocycles, and α-ketocarboxyls (Kawasaki et al. 1989; Tao et al. 1998), and natural compounds such as leupeptin (Mehdi 1991). Unfortunately, these inhibitors lack specificity, and attempt to improve them lead to loss of potency; additional problems to be surpassed are membrane permeability and solubility (Low et al. 2016).

Calpastatin is the natural endogenous inhibitor of calpains, and it is highly specific; its specificity is determined by the simultaneous binding of three calpastatin subdomains to both subunits of heterodimeric calpains (Battaglia et al. 2003; Carragher, 2006). Considering that the entire protein poorly penetrates the cells, fusion proteins containing a calpastatin peptide and a signal sequence capable of delivering the fusion protein into the cells have been produced and patented (reviewed by Donkor, 2015). Also, taking into consideration the mode of action of calpastatin, i.e. a β-turn loop within calpastatin forms a broad interaction around the active site cysteine that inhibits the enzyme, a library of peptidic compounds was constructed and are under test (Low et al. 2016). There are some promising results on Ki with a 1000-fold selectivity for calpain compared with cathepsin L (Jiao et al. 2010).

Calpains in Trypanosomatids

Although calpains are well described in mammalian cells as well as its physiological roles and involvement in pathological disorders, in trypanosomatids, the picture is different. Calpains have a wide variety of domains in addition to the peptidase domain, such as calcium binding and penta-EF-hand domains. The calpain superfamily is divided into several subfamilies according to the structures of these additional domains. Since the mammalian conventional calpain catalytic subunits are the reference point for calpain structure, calpains having a similar domain structure are called ‘classical’ calpains in contrast to ‘non-classical’ ones that may lack one or all of these domains, including the peptidase domain. Non-classical calpain peptidase domains have amino acid identities with each other ranging from<25% to >75%, and they may have other functional domains in aleatory regions of the protein (Sorimachi et al. 2011). In addition, several of these non-classical calpains have alterations in the catalytic triad leading to proteins devoid of proteolytic activity.

A survey on trypanosomatid genome revealed a total of 18 calpain-like sequences in T. brucei, 24 in T. cruzi and 27 in Leishmania major (Ersfeld et al. 2005). Among these, some proteins present the catalytic triad conserved, which supports the idea that calpains may have proteolytic activity in trypanosomatids. However, these enzymes are tricky to detect biochemically, and may be readily hydrolyzed by other abundant peptidases. In this sense, calpain proteolytic activity was never demonstrated in T. cruzi or Leishmania spp. However, in Angomonas deanei (formerly Crithidia deanei), a monoxenic trypanosomatid, a proteolytically active cysteine peptidase was purified and presented several biochemical characteristics of calpains, such as neutral pH and low activity upon ions chelation, which was recovered after calcium restoration. Although the amino acid sequence of the purified protein was not demonstrated, the protein cross reacted with antibodies raised against an atypical calpain from Drosophila melanogaster (d’Avila-Levy et al. 2003). Also, two reports suggest the presence of a calcium-dependent cysteine peptidase in Leishmania donovani, but the molecular identity of the enzyme was also not assessed (Bhattacharya, Dey & Datta 1993; Dey et al. 2006). Therefore, more efforts should be directed to ascertain whether calpains are proteolytically active in trypanosomatids.

Considering the high number of genes and sequence diversity of calpains in trypanosomatids, it is not an easy task to completely characterize this protein family and to assess its functions. Up to
| Inhibitors name, Alias | Most important structures | Commercial availability | Notes |
|-----------------------|---------------------------|-------------------------|-------|
| A-705253, ABT-957     | (N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethylaminomethylphenyl) ethen-1-yl]benzamide | Abbvie Inc. | In Phase I clinical trial to treat Alzheimer’s Disease (ClinicalTrials.gov Identifier: NCT0222073) Safety and efficacy established in animals models to treat cataracts, and currently undergoing confirmatory preclinical studies in human lens model to progress to clinical trials (Morton et al. 2013). |
| CAT811                | ((7S,10S,13S)-7-Formyl-10-isobutyl-9,12-dioxo-2-oxa-8,11-di diazabicyclo[13·2·2]nonadeca-1(18),15(19),16-trien-13-yl)-carbamic Acid Benzyl Ester | Calpain Therapeutics Pty Ltd. | Safety and efficacy established in animals models to treat cataracts, and currently undergoing confirmatory preclinical studies in human lens model to progress to clinical trials (Morton et al. 2013). |
| PD150606 and PD151746| 3-(4-Iodophenyl)-2-mercapto-(Z)-2-propenoic acid, and 3-(5-Fluoro-3-indolyl)-2-mercapto-(Z)-2-propenoic acid | Merck Millipore Co. | Although high selective to calpains in preclinical studies to treat muscular disorders, analogues are under development to favour inhibition of calpain-1 over calpain-2 |
| E-64 and derivates    | [L-trans-3-Carboxyoxirane-2-carbonyl]-L-Leu-agmatine | Sigma Aldrich Co., Merck Millipore Co., Peptide Inst. and Bachem AG. | Safety and efficacy of such compounds had already been demonstrated in preclinical and (Hook et al., 2007) and clinical studies (Satoyashi, 1992), but strategies for enhancing the selectivity for calpain isoforms should be enhanced |
| Calpain Inhibitor III, MDL-28170 and analogs | Carbobenzoxy-valinyl-phenylalaninal | Merck Millipore Co., Sigma Aldrich Co., Bachem AG. and Enzo Life Sciences Inc. | A powerful and cell-permeable calpain inhibitor (Mehdi, 1991), but presents cross reactivity with cathepsins B and L. Novel highly selective analogues provided promising *in vitro* results (Kim et al., 2011) |
| Leupeptin derivates   | Ac-Leu-Leu-L-Argininal | Sigma Aldrich Co., Peptide Inst. and Bachem AG | Derivates of leupeptin are under development as a means of facilitating penetration of the inhibitor into the cells (reviewed by Donkor, 2011). Relatively selective inhibitor of calpain-1 rather than calpain-2 presenting promising results in Alzheimer’s disease in preclinical studies (Battaglia et al., 2003) |
| BDA-410               | (2S)-N-[(1S)-1-[(S)-Hydroxy(3-oxo-2-phenyl-1-cyclopropen-1-yl)methyl]-2-methylpropyl]-2-benzenesulfonoylamino-4-methylpentanamide | Mitsubichi Tanabe Pharma Co. | |
now, there is no knockout available. However, in T. brucei, the RNAi of three calpain genes revealed their roles in parasite growth, morphology and flagellum assembly (Olego-Fernandez et al. 2009; Hayes et al. 2014).

There are several other evidences on the relevance of calpain molecules for Leishmania life cycle disclosed by unbiased assays, such as transcriptomics and proteomics approaches (reviewed by Branquinha et al. 2013). When highly sensitive gene expression microarray technology was employed to identify genes that are differentially expressed in L. donovani isolated from post kala-azar dermal leishmaniasis (PKDL) patients in comparison with those from visceral leishmaniasis, a 2-fold higher expression of five proteins in PKDL parasites was reported, including a short calpain (Salotra et al. 2006). In another approach, a comparative proteomics screen between antimonial-resistant and -sensitive L. donovani strains isolated from kala-azar patients revealed a calpain-related protein SKCRP14·1, which is downregulated in the resistant strain, and modulate the susceptibility to antimonials and miltefosine by interfering with drug-induced programmed cell death (PCD) pathways: when over-expressed, this calpain significantly increased the sensitivity of the resistant strain to antimonials and miltefosine-treated cells, in which this calpain molecule protected against miltefosine-induced PCD. It was concluded that the calpain SKCRP14·1 is likely to be a regulator of PCD (Vergnes et al. 2007). As a matter of fact, conflicting roles for calpain activity in contributing to the promotion and/or suppression of apoptosis have been proposed in mammals, being suggested that calpains must have a wide influence over many apoptotic processes, and their specific roles during apoptosis may differ depending on the cell type and the nature of the apoptotic stimulus. In L. major differentiation from procyclic-into-metacyclic promastigotes, one calpain gene was shown to be upregulated in the procyclic promastigote insect stage, while two distinct calpains were upregulated in the metacyclic insect stage through DNA microarray analysis. Life cycle-specific expression may also demarcate the search for specific functions of these calpains (Saxena et al. 2003). In trypanosomatids, it is possible that the great expansion of the calpain family in the parasite genome together with the variety in calpains structure in comparison with the mammalian calpains may contribute to the variety of functions performed (Ersfeld et al. 2005; Branquinha et al. 2013).

The link between the available calpain inhibitors and a ‘me-too’ or repurpose approaches for leishmaniasis chemotherapy encouraged our research group to assess the effects of a calpain inhibitor against pathogenic trypanosomatid parasites (d’Avila-Levy et al. 2006; Sangenito et al. 2009; Ennes-Vidal et al. 2010, 2011; Branquinha et al. 2013; Marinho et al. 2014). MDL28170 (Cbz-Val-Phe-H) is a potent, cell-permeable, synthetic and reversible peptide inhibitor of calpain I and II, also known as calpain inhibitor III (Mehdi 1991). Up to now, this compound showed promising results in pre-clinical studies in vitro with some Leishmania species. MDL28170 interfered in various steps of the parasite life cycle and incited our research group to program further studies to better understand the calpain functions in these organisms. Our results showed that MDL28170 was capable of arresting irreversibly the growth of L. amazonensis promastigotes in a dose-dependent manner (d’Avila-Levy et al. 2006), while one possible mechanism of action is through the activation of an apoptotic-like pathway (Marinho et al. 2014). Unpublished results from our research group indicate that MDL28170 is also capable of arresting the
development of two Leishmania species in host cells. MDL28170 was also effective against all the morphological stages found in T. cruzi, including bloodstream trypomastigote, the most infective stage of the parasite (Sangenito et al. 2009; Ennes-Vidal et al. 2010). In addition, either the treatment of T. cruzi with MDL28170 prior to host cell infection, or the post-infection treatment, considerably reduced infection (Ennes-Vidal et al. 2010). The calpain inhibitor also arrested the in vitro metacyclogenesis of T. cruzi and impaired parasite adhesion (epimastigote forms) to the gut of the insect vector Rhodnius prolixus in a dose-dependent manner (Ennes-Vidal et al. 2011). Interestingly, the compound did not display any relevant cytotoxic effect on mammalian host cells in the concentrations that caused a considerably reduction on the parasite development in the host cells. It is possible that the parasite may concentrate the inhibitor, or even that the diversity of cysteine peptidases in the host cells may surpass the functions blocked by the inhibitor, thus reinforcing the possibilities for chemotherapeutic intervention. Nevertheless, it should be pointed out that MDL28170 as other calpain inhibitors may also act on other parasite peptidases, also the micromolar concentration required for activity may reflect the low affinity to a possible calpain target or even its action on other unpredicted targets. However, its action even in the micromolar ranges encourages the pursuit calpains and calpain inhibitors as a possible chemotherapeutic approach, but with several challenges: identify, purify and characterize an active calpain; determine its structure; identify and select possible inhibitors and test these inhibitors in pre-clinical assays. Also, the new generation of calpain inhibitors should be continuously checked for anti-leishmanial activity.

Concluding remarks

Here, we discuss the repurpose approach as a viable economic alternative to circumvent the bottlenecks of drug discovery pipeline, particularly in neglected disease. There are already examples of a blockbuster success of repurpose drug, such as the Pfizer’s Viagra (Sildenafil), which is used to combat erectile dysfunction. Initially, the drug was developed for heart disease treatment, but the observation that penile erections were a common side effect in phase I trials led to pilot studies with Sildenafil in male erectile dysfunction (Ghofrani et al. 2006). Interestingly, in Leishmania, there is already an example of a repurpose drug. Miltefosine was initially described with antiprotozoal and antineoplastic, however, the application of this compound in an oral formulation in the treatment of different tumours was discontinued, and the successful trials outcomes in India led to approval of the compound for the treatment of visceral leishmaniasis (Dorlo et al. 2012). Therefore, a repurpose approach with approved inhibitors could be an interesting shortcut for the treatment of leishmaniasis, and considering that calpain inhibition is an explored pathway to treat strokes, diabetes and Parkinson’s disease, among others, including the possible prevention of spinal cord injury and permanent disability, we advocate that calpain inhibitors should be explored as potential chemotherapeutic agents to treat leishmaniasis. Likewise, other compounds or inhibitors suitable for a repurpose approach should be explored by the scientific community. Also, the calpain family needs more efforts to better characterize it in trypansomatids, improving not only our knowledge on this intriguing family of peptidases, but also helping in rational drug design approaches.

ACKNOWLEDGEMENTS

The authors are grateful to CAPES, CNPq, FAPERJ and FIOCRUZ fellowships and also to Dr. Malachy McCann from Maynooth University for drawing the chemical structures of the calpain inhibitors.

FINANCIAL SUPPORT

Our research groups are supported by grants from the Brazilian Agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa no Estado do Rio de Janeiro (FAPERJ) to R. S. F. Menna-Barreto, M. H. Branquinha, A. L. S. Santos and C. M. d’Avila-Levy; Fundação Oswaldo Cruz (FIOCRUZ) to R. S. F. Menna-Barreto and C. M. d’Avila-Levy; and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) to C. M. d’Avila-Levy. André L.S. Santos, Marta H. Branquinha, Silvia A. G. da-Silva, Rubem S. F. Menna-Barreto and Claudia M. d’Avila-Levy are also supported by CNPq and FAPERJ fellowships.

REFERENCES

Alvar, J., Yactayo, S. and Bern, C. (2006). Leishmaniasis and poverty. Trends in Parasitology 22, 552-557.
Alvar, J., Velez, I. D., Bern, C., Herrer, M., Desjeux, P., Cano, J., Jannin, J. and den Boer, M. (2012). Leishmaniasis worldwide and global estimates of its incidence. PloS ONE 7, e35671.
Andrews, K. T., Fisher, G. and Skinner-Adams, T. S. (2014) Drug repurposing and human parasitic protozoan diseases. International Journal for Parasitology: Drugs and Drug Resistance 4, 95–111.
Angelastro, M. R., Meldi, S., Burkhart, J. P., Peet, N. P. and Bey, P. (1990). Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteases. Journal of Medicinal Chemistry 33, 11-13.
Ashburn, T. T. and Thor, R. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery 3, 673–683.
Battaglia, F., Trinchese, F., Liu, S., Walter, S., Nixon, R. A. and Arancio, O. (2003). Calpain inhibitors, a treatment for Alzheimer’s disease: position paper. Journal of Molecular Neuroscience 20, 357–362.
Bhattacharya, J., Dey, R. and Datta, S. C. (1993). Calcium dependent thiol protease caldonopain and its specific endogenous inhibitor in Leishmania donovani. Molecular and Cellular Biochemical 126, 9–16.
Boelaert, M., Mcheus, F., Robays, J. and Lutumba, P. (2010). Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. Annual Tropical Medicinal Parasitology 104, 535–542.
Branquinha, M. H., Marinho, F. A., Sangenito, L. S., Oliveira, S. S. C., Gonçalves, K. C., Ennes-Vidal, V., d’Avila-Levy, C. M. and Santos, A. L. S. (2013). Calpains: potential targets for alternative

Vitor Ennes-Vidal and others

122
Calpain inhibitors to treat leishmaniasis

chemotherapeutic intervention against human pathogenic trypanosomatids. Current Medicinal Chemistry 20, 3174–3185.

Carragher, N. O. (2006). Calpain inhibition: a therapeutic strategy targeting multiple disease states. Current Pharmaceutical Design 12, 615–638.

Cavalli, A. and Bolognesi, M. L. (2009). Neglected tropical diseases: multiple-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. Journal of Medicinal Chemistry 52, 7339–7359.

d’Avila-Levy, C.M., Souza, R.F., Gomes, R.C., Vermelho, A.B. and Branquinha, M.H. (2003). A novel extracellular cysteine proteinase from Crithidia fasciculata: cloning, expression and functional analysis. Archives of Biochemical and Biophysical, 420, 1–8.

d’Avila-Levy, C.M., Marinho, F.A., Santos, I.L. O., Martins, J. L. M., Santos, A. L. S. and Branquinha, M. H. (2006). Antileishmanial activity of MDL28170, a potent calpain inhibitor. International Journal of Anti-Infective Therapy 12, 138–142.

Scully, C. C., Davies, P. L., Yudin, A.K. and Zaretsky, S. (2016). Rational design of calpain inhibitors based on Calpastatin Peptidomimetics. Journal of Medical Chemistry 59, 5403–5415.

Machado-Silva, A., Guimarães, R. C., Tavares, C. A. and Sinisterra, R. D. (2015). New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape. Expert Opinion on Therapeutic Patents 25, 247–260.

Marinho, F.A., Gonçalves, K.C., Oliveira, S.S.C., Gonçalves, D.S., Matteelli, F.P., Seabra, S.H., Oliveira, A.C.S., Bellio, M., Oliveira, S.S., Souto-Padrón, T., d’Avila-Levy, C.M., Santos, A.L.S. and Branquinha, M.H. (2014). The calpain inhibitor MDL28170 induces the expression of apoptotic markers in Leishmania amazonensis promastigotes. PLoS ONE 9, e87659.

Santos, A. L. S. and Branquinha, M. H. (2008). Ersfeld, K., Barraclough, H. and Gull, K. (2001). Evolutionary reclassification of kinetoplastid parasites. Nature Structural Biology 8, 54–57.

Bicerضا, H., Elad, H.Y., Kanakia, H. S. and Branquinha, M. H. (2014). The calpain inhibitor MDL28170 reduces brain betaamyloid and beta-secretase activity and induces major transitions in trypanosome morphology. Cellular Biology 206, 377–384.

Morton, J.D., Lee, H.Y., McDermott, J.D., Robertson, L.J., Bickerstaffe, R., Jones, M.A., Coxon, J.M. and Abell, A.D. (2013). A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model. Investigative Ophthalmology and Visual Science 54, 359–385.

Nwaka, S. and Hudson, A. (2006). Innovative lead discovery strategies for tropical diseases. Nature Reviews Drug Discovery 5, 941–955.

Olego-Fernandez, S., Vaughan, S., Shaw, M.K., Gull, K. and Ginger, M.L. (2009). Cell morphogenesis of Trypanosoma brucei requires the paralogue, differentially expressed calpain-related proteins CAPS-5 and CAPS-5’.

Taylor, G.J. and Wainwright, P. (2009). Erythrocyte invasion of Trypanosoma brucei by modulating drug-induced programmed cell death. Molecular and Cellular Proteomics 8, 88–101.

Thrombin: A multiple disease state therapeutic target. Expert Opinion on Therapeutic Patents 21, 601–636.

Donkor, I.O. (2015). An updated patent review of calpain inhibitors (2012–2014). Expert Opinion on Therapeutic Patents 25, 17–33.

Donkor, I.O. (2011). Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opinion on Therapeutic Patents 21, 19–27.

Wang, K.K., Nath, R., Posner, A., Raser, K.J., Buroker-Kilgore, M., Wainwright, P., Myler, P.J. and Flotte, T.R. (2013). E-64-d, a selective calpain inhibitor, is neuroprotective. Proceedings of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis 60, 150–153.

Zhang, Z., Huang, Z., Dai, H., Wei, L., Sun, S. and Gao, F. (2015). Therapeutic potential of calpain: new aspects. Drug Discovery Today 21, 917–923.

Salez, M.E., Ramireze-Lorca, R., Moranon, F.J. and Ruiz, A. (2006). The therapeutic potential of the calpain family: new aspects. Drug Discovery Today 31, 841–846.

Hook, G., Hook, V.Y. and Kindy, M. (2007). Cysteine protease inhibitors reduce brain betaamyloid and beta-secretase activity in vitro and are potent Alzheimer’s disease therapeutics. Biological Chemistry 388, 979–983.

Huang, Y. and Wang, K.K. (2001). The calpain family and human disease. Trends in Molecular Medicine 7, 355–362.

Jia, S., McDonald, D.Q., Coxon, J.M. and Parker, E.J. (2010). Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. Biochemistry 49, 5533–5539.

Kawasaki, H., Emori, Y., Imajoh-Ohmi, S., Minami, Y. and Sorimachi, H. (2001). The calpain family and human disease. Trends in Molecular Medicine 7, 355–362.

Kim, S.H., Lee, Y.H., Jung, S.Y., Kim, H.J., Jin, C. and Lee, Y.S. (2011). Synthesis of chromosome carbonamide derivatives with antioxidant and calpain inhibitory properties. European Journal of Medicinal Chemistry 46, 1721–1728.

Kwok, A.K. and Koenigbauer, F.M. (2015). Incentives to repurpose existing drugs for orphan indications. ACS Medicinal Chemistry Letters 6, 38–39.

Low, K.E., Ler, S., Chen, K.J., Campbell, R.L., Hickey, J.L., Tan, J., Scully, C.C., Davies, P.L., Yudin, A.K. and Zaretsky, S. (2016). Calpain inhibitors to treat leishmaniasis. Current Medicinal Chemistry 20, 3174–3185.